Motilal Oswal Asset Management Company Limited, acting as the investment manager to the schemes of Motilal Oswal Mutual Fund, has reported the disposal of shares in HealthCare Global Enterprises Ltd. under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The transaction was executed on May 4, 2026, through open market transactions, and the disclosure was filed with BSE Limited on May 07, 2026.

Transaction Overview

The disposal was carried out collectively by eight schemes of Motilal Oswal Mutual Fund, which are considered as persons acting in concert (PAC) for the purpose of this disclosure. The acquirer does not belong to the promoter or promoter group of the target company. The following schemes participated in the transaction:

• Motilal Oswal BSE Healthcare ETF
• Motilal Oswal Nifty Microcap 250 Index Fund
• Motilal Oswal Multi Cap Fund
• Motilal Oswal Business Cycle Fund
• Motilal Oswal Services Fund
• Motilal Oswal BSE 1000 Index Fund
• Motilal Oswal Special Opportunities Fund
• Motilal Oswal Consumption Fund

Shareholding Details Before and After Disposal

The following table summarises the change in shareholding position of Motilal Oswal Mutual Fund in HealthCare Global Enterprises as a result of the disposal:

Target Company Capital Structure

The equity share capital of HealthCare Global Enterprises Ltd. remained unchanged following the disposal. Key details of the target company's capital structure are presented below:

Regulatory Disclosure

The disclosure was made by Aparna Karmase, Head – Compliance, Legal and Secretarial at Motilal Oswal Asset Management Company Limited, from Mumbai, dated May 07, 2026. The filing is in compliance with the prescribed format under SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, which mandates disclosure whenever an acquirer's shareholding crosses specified thresholds through acquisition or disposal of shares.

HealthCare Global Enterprises Limited , India's largest cancer care provider operating under the brand "HCG", has announced two key investor events surrounding its audited financial results for the quarter and financial year ended March 31, 2026. The company's Board of Directors is scheduled to meet on Tuesday, May 19, 2026, to consider and approve the audited financial results — both standalone and consolidated. Following the board meeting, an Earnings Conference Call has been scheduled for Wednesday, May 20, 2026, at 1:30 pm IST, to discuss the declared financial results with investors and analysts. The intimation has been filed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Meeting and Earnings Call Details

The following table summarises the key details of both the board meeting and the earnings conference call:

Earnings Conference Call

The earnings conference call will be led by the senior management of HealthCare Global Enterprises Limited. The call will commence with a brief management discussion on the Q4 & FY26 results, followed by an interactive Question & Answer session for investors and analysts. Participants can pre-register via the provided link to connect without waiting for an operator. For updates and specific queries, investors may visit www.hcgel.com or write to investors@hcgoncology.com . Investors may also reach out to CDR India — Anoop Poojari at +91 98330 90434 / anoop@cdr-india.com or Suraj Digawalekar at +91 98211 94418 / suraj@cdr-india.com .

Trading Window Closure

In accordance with the company's code of conduct framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in shares of the company has been closed for all designated persons and their immediate relatives. The closure period commenced on April 1, 2026, and shall remain closed until 48 hours after the declaration of the financial results.

About HealthCare Global Enterprises Limited

HealthCare Global Enterprises Limited, headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 25 hospitals across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centres provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. The company also has a presence in the fertility segment under the "Milann" brand. The company's official website is available at https://www.hcgoncology.com/ .